Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection
Top Cited Papers
- 3 September 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (18), 5843-5855
- https://doi.org/10.1021/jm800245z
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialThe Lancet, 2007
- Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 ActivityAntimicrobial Agents and Chemotherapy, 2005
- Integrase inhibitors to treat HIV/AidsNature Reviews Drug Discovery, 2005
- Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus MacaquesScience, 2004
- Discovery of α,γ-Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA PolymeraseJournal of Medicinal Chemistry, 2003
- Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion InhibitorClinical Infectious Diseases, 2003
- Design and Synthesis of 8-Hydroxy-[1,6]Naphthyridines as Novel Inhibitors of HIV-1 Integrase in Vitro and in Infected CellsJournal of Medicinal Chemistry, 2003
- Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymesProceedings of the National Academy of Sciences of the United States of America, 2002
- Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in CellsScience, 2000
- HIV Integrase Structure and FunctionPublished by Elsevier BV ,1999